Lv2
118 积分 2024-11-03 加入
EMPEROR-Reduced: Empagliflozin and Outcomes in Heart Failure and CKD
1天前
待确认
Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non‐diabetic chronic kidney disease
1天前
已完结
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
1天前
已完结
Effectiveness and Safety of Dapagliflozin for Black and White Patients With Chronic Kidney Disease in North and South America
1天前
已完结
Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions
1天前
已完结
WCN23-0666 EFFICACY AND SAFETY OF DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE ACROSS THE SPECTRUM OF FRAILTY
1天前
已完结
#5217 PROTOCOL AND PRELIMINARY RESULTS OF DAPAGLIFLOZIN IN INACTIVE LUPUS NEPHRITIS CROSS-OVER RANDOMIZED TRIAL
1天前
待确认
Effect of empagliflozin on all-cause hospitalization in EMPA-KIDNEY
1天前
已完结
#3318 PHASE II DOSE-SELECTION, RANDOMISED DOUBLE-BLIND TRIAL OF THE ASI, BI 690517, ALONE AND IN COMBINATION WITH EMPA IN PEOPLE WITH CKD
1天前
已完结
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial
1天前
已完结
皖公网安备34019202002308
